In recent years, novel classes of small hetero-bifunctional compounds have been developed as tools for the treatment of cancer and other diseases through different approaches, from radio/chemotherapy and imaging to immunotherapy and protein degradation. Within this growing research area, progresses in ligand-screening procedures and hit-to-lead optimizations, together with advances in drug-release technologies, are paving the way to the future treatment of a broad range of pathologies with small targeted therapeutics.
Targeted Small-Molecule Conjugates: the Future is Now / A. Dal Corso. - In: CHEMBIOCHEM. - ISSN 1439-4227. - (2020). [Epub ahead of print]
Targeted Small-Molecule Conjugates: the Future is Now
A. Dal Corso
Ultimo
2020
Abstract
In recent years, novel classes of small hetero-bifunctional compounds have been developed as tools for the treatment of cancer and other diseases through different approaches, from radio/chemotherapy and imaging to immunotherapy and protein degradation. Within this growing research area, progresses in ligand-screening procedures and hit-to-lead optimizations, together with advances in drug-release technologies, are paving the way to the future treatment of a broad range of pathologies with small targeted therapeutics.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Postprint.pdf
Open Access dal 08/09/2021
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
284.48 kB
Formato
Adobe PDF
|
284.48 kB | Adobe PDF | Visualizza/Apri |
|
cbic.202000507.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
3.62 MB
Formato
Adobe PDF
|
3.62 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
